| 1 |
34327872 | Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. | 2022 May |
5 |
| 2 |
35052828 | Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. | 2022 Jan 11 |
1 |
| 3 |
35204377 | Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. | 2022 Jan 23 |
1 |
| 4 |
33298588 | EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1. | 2021 Feb |
4 |
| 5 |
33556172 | Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. | 2021 Jun 1 |
5 |
| 6 |
34388391 | Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. | 2021 Sep 2 |
1 |
| 7 |
34682775 | RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. | 2021 Oct 11 |
2 |
| 8 |
34830914 | hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. | 2021 Nov 17 |
3 |
| 9 |
31711924 | ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. | 2020 Feb |
4 |
| 10 |
31778273 | Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. | 2020 Feb |
4 |
| 11 |
32014934 | Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. | 2020 Feb |
1 |
| 12 |
32457256 | Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer? | 2020 May 31 |
1 |
| 13 |
32671914 | Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. | 2020 Nov |
2 |
| 14 |
32816368 | Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. | 2020 Oct |
1 |
| 15 |
32878779 | New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. | 2020 Sep |
3 |
| 16 |
33142664 | "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. | 2020 Oct 31 |
5 |
| 17 |
33287390 | Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. | 2020 Dec 3 |
1 |
| 18 |
30528800 | Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments. | 2019 Jan |
1 |
| 19 |
30867652 | Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. | 2019 |
1 |
| 20 |
31113844 | Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. | 2019 Aug 15 |
3 |
| 21 |
31255992 | Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. | 2019 Sep |
2 |
| 22 |
31504065 | In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. | 2019 |
1 |
| 23 |
31752123 | hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. | 2019 Nov 18 |
3 |
| 24 |
29515256 | Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. | 2018 Apr |
1 |
| 25 |
29963262 | The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. | 2018 Jun 15 |
2 |
| 26 |
30143259 | GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1. | 2018 Sep 18 |
3 |
| 27 |
30214194 | Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. | 2018 |
5 |
| 28 |
30557411 | Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. | 2018 |
10 |
| 29 |
28196013 | Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. | 2017 May/Jun |
1 |
| 30 |
28199010 | Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. | 2017 Mar |
3 |
| 31 |
28365185 | Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. | 2017 May 15 |
3 |
| 32 |
28396636 | Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. | 2017 |
1 |
| 33 |
28476815 | Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. | 2017 May |
4 |
| 34 |
28641307 | Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. | 2017 Jul 25 |
8 |
| 35 |
28693211 | Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. | 2017 Jul |
4 |
| 36 |
28765935 | FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. | 2017 Oct |
4 |
| 37 |
28770102 | A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. | 2017 Jul |
6 |
| 38 |
29064388 | The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance. | 2017 Oct 24 |
4 |
| 39 |
26266900 | Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients. | 2016 Apr |
4 |
| 40 |
26742940 | Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. | 2016 Oct |
5 |
| 41 |
26784908 | Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. | 2016 May-Jun |
1 |
| 42 |
27032872 | Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. | 2016 May |
10 |
| 43 |
27245475 | Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. | 2016 Nov |
2 |
| 44 |
27247050 | Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. | 2016 Aug |
7 |
| 45 |
27604902 | TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. | 2016 Nov 1 |
2 |
| 46 |
25298108 | Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. | 2015 Feb |
2 |
| 47 |
25519698 | Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy? | 2015 Jan |
1 |
| 48 |
25672581 | p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. | 2015 Jul |
3 |
| 49 |
25998688 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. | 2015 Jul |
1 |
| 50 |
26037416 | Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2. | 2015 Sep |
1 |